SubsidieMeestersPreventing rejection and ensuring survival of grafts
This project aims to enhance organ transplant success by using Listeria monocytogenes to protect grafted cells from T-cell killing, reducing reliance on immunosuppressive drugs and improving patient outcomes.
Projectdetails
Introduction
The success of organ transplantation depends on the lifelong use of immunosuppressive drugs to prevent rejection of the donor cells by the recipient’s immune system.
Limitations of Immunosuppressive Drugs
These immunosuppressive drugs have several limitations, most notably major side effects, namely:
- Opportunistic infections
- Cancers
Project Aim
We have recently shown that the bacterial pathogen Listeria monocytogenes (Lm) induces the resistance of infected cells to T-cell mediated killing. This project aims to protect grafted cells from T-cell mediated killing and thereby mitigate organ rejection.
Future Prospects
This will lay the groundwork for:
- Patent filing
- Establishment of a robust business model to ensure further development and clinical translation
Expected Outcomes
This innovative approach is expected to reduce the need for immunosuppressive therapy in transplant recipients, thereby improving outcomes and quality of life for the 130,000 patients who receive transplants worldwide each year.
Research Basis
This proof-of-concept project is based on our recently published study (Maudet et al, Nature 2022) supported by the ERC Invadis grant.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-2-2025 |
| Einddatum | 31-7-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- INSTITUT PASTEURpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Integrated AI-Driven Systems For Kidney Transplant Precision Medicine (AI-Care)The ERC AI-Care project aims to enhance long-term kidney transplant outcomes through personalized, non-invasive monitoring and advanced diagnostic technologies for rejection risk assessment. | ERC Consolid... | € 1.997.935 | 2024 | Details |
MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus host disease and cure leukemia relapseThe "MICROBOTS" project aims to characterize gut microbiome signatures in allo-SCT patients to enhance antitumor responses and reduce GVHD through precision fecal microbiota transplantation. | ERC Consolid... | € 1.999.901 | 2024 | Details |
Novel histocompatibility loci in manThis project aims to identify unknown histocompatibility loci in transplantation using a pluri-omics approach to improve understanding and treatment of graft-versus-host disease and chronic rejection. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapseAlloCure aims to identify and target pathogenic signaling in immune and leukemia cells to develop personalized therapies that reduce mortality from GVHD and leukemia relapse post-allo-HCT. | ERC Advanced... | € 2.498.943 | 2023 | Details |
Integrated AI-Driven Systems For Kidney Transplant Precision Medicine (AI-Care)
The ERC AI-Care project aims to enhance long-term kidney transplant outcomes through personalized, non-invasive monitoring and advanced diagnostic technologies for rejection risk assessment.
MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus host disease and cure leukemia relapse
The "MICROBOTS" project aims to characterize gut microbiome signatures in allo-SCT patients to enhance antitumor responses and reduce GVHD through precision fecal microbiota transplantation.
Novel histocompatibility loci in man
This project aims to identify unknown histocompatibility loci in transplantation using a pluri-omics approach to improve understanding and treatment of graft-versus-host disease and chronic rejection.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.
Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapse
AlloCure aims to identify and target pathogenic signaling in immune and leukemia cells to develop personalized therapies that reduce mortality from GVHD and leukemia relapse post-allo-HCT.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Bottom-up manufacturing of artificial anti-tumor T cellsThe project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment. | EIC Pathfinder | € 3.391.796 | 2024 | Details |
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemiaThe project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes. | EIC Transition | € 2.497.500 | 2023 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune systemi-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028. | EIC Accelerator | € 2.495.510 | 2023 | Details |
Bottom-up manufacturing of artificial anti-tumor T cells
The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
The project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes.
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
i-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028.